Faurecia
Maintenance Supervisor
Devon Facility Management Llc. Oct 2012 - Oct 2013
Supervisor
Faurecia Apr 2012 - Oct 2012
Operator
Fca Fiat Chrysler Automobiles Aug 2005 - Sep 2007
Materials Specialist
Skills:
Facilities Management Building Maintenance Maintenance Management Preventive Maintenance Carpet Cleaning Supervisory Skills Contract Management Team Building Process Improvement Continuous Improvement Customer Service 5S Troubleshooting Training Manufacturing Forklift Operation Automotive Kaizen Lean Manufacturing Six Sigma Root Cause Analysis
Needham analyst Chad Messer cut his 2017Exondys 51 sales expectations to $109 million from $183 million.He also lowered his price target on Sarepta stock to 75 from 78, though kept his outperform rating.
Date: Mar 01, 2017
Category: Business
Source: Google
Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar
The exit of the FDA staff member, Dr. Ron Farkas, is a plus for the Sarepta drug, but not the biggest plus, Needham analyst Chad Messer said in a research note Wednesday, in which he hiked his price target on Sarepta stock to 47 from 26. Farkas "was notthe only skeptic and frankly we do not believ
Date: Sep 14, 2016
Category: Business
Source: Google
Esperion Therapeutics Inc Bolts Higher As Cholesterol Drug Aces Mid-Stage Study
According to Needham & Co analyst Chad Messer, ETC-1002 stands a better chance of being used in conjunction with statins, rather than as a separate treatment. This brings the drug's market to around 10 million patients 30% of the 35 million patients who didnt respond well to statin treatment.
makers have been developing the ETC -1002 as an additional therapy to statins or an alternative for those who are intolerant to statins. Needham & Co analyst Chad Messer informed that instead of replacing statins altogether he is expecting the drug to be adopted quicker as an additional therapy.
Date: Mar 18, 2015
Category: Health
Source: Google
Data shows Sarepta's muscular dystrophy treatment is effective
While the company, Sarepta Therapeutics, hailed the results as positive, they apparently were not positive enough for investors, who dumped the stock when markets opened. Chad Messer, an analyst with Needham & Co LLC, a New York investment firm, said he was puzzled by the markets reaction.